Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (NASDAQ: EOLS), a leading performance beauty company, will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The event will feature members of its management team, with an audio webcast available on demand starting at 7:00 am ET. Evolus focuses on innovative products tailored for beauty consumers, highlighting its flagship product, Jeuveau®, which is dedicated exclusively to aesthetics. More details are available on Evolus' website.
Evolus, Inc. (NASDAQ: EOLS) announced promising results from a peer-reviewed analysis showing that male patients treated with Jeuveau® achieved approximately 10% higher responder rates compared to those receiving BOTOX® in a Phase III trial. The analysis, involving 56 males, indicated a consistent trend favoring Jeuveau® despite not reaching statistical significance due to the small sample size. The increasing popularity of botulinum toxin treatments among men, which rose by 380% from 2000 to 2018, highlights the market potential for Jeuveau® in this demographic.
Evolus, Inc. (NASDAQ: EOLS) reported a 42% increase in Q2 2022 net revenue to $37.2 million, driven by higher volumes and a greater average selling price of Jeuveau®. The company anticipates achieving the upper end of its full-year 2022 guidance of $143 to $150 million, with projected year-over-year growth of nearly 50%. Evolus is set to launch Nuceiva® in Europe in Q3 2022 and maintains a strong cash position of $84.5 million. However, operating expenses rose to $58.5 million, resulting in a loss from operations of $21.3 million.
Evolus, Inc. (NASDAQ: EOLS) will announce its second quarter 2022 financial results on August 2, 2022, before U.S. markets open. A conference call will be held at 9:00 a.m. ET to discuss the results, followed by a Q&A session. Investors can participate by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or via a live webcast accessible on Evolus' website. A replay of the call will be available afterwards. Evolus focuses on the aesthetic neurotoxin market, primarily with its product Jeuveau, designed for beauty consumers.
Evolus (NASDAQ: EOLS) has launched its largest consumer engagement program, "Switch Your Tox and Love Evolus Forever," aimed at increasing adoption of its neurotoxin product, Jeuveau®. The campaign offers $160 off treatments for new patients at participating practices, starting September 1. This initiative includes incentives for injectors, such as product discounts and marketing support. Since its launch, Jeuveau has been administered in approximately 2 million treatments, highlighting the demand for the product in the aesthetic market.
Evolus, Inc. (NASDAQ: EOLS) has completed patient enrollment for a clinical study assessing an 'extra-strength' dosing option for its neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs). Expected interim results are due in the first half of 2023. The multicenter study involves 150 patients over 12 months and aims to evaluate the safety, efficacy, and duration of Jeuveau® at 40 units compared to existing doses. The company anticipates that this new option could meet diverse patient needs and enhance treatment customization.
Evolus (NASDAQ: EOLS) announced a post hoc analysis published in Dermatologic Surgery showcasing the effectiveness of Jeuveau® among millennials. The analysis indicated that 100% of participating millennials experienced over a 1-point improvement in the Glabellar Line Scale at days 7, 14, and 30. Additionally, 100% reported satisfaction with the treatment. Jeuveau® was well-tolerated across both millennial and non-millennial demographics, with similar adverse event rates. This study emphasizes the product's appeal within the millennial market, a crucial segment for aesthetic treatments.
Summary not available.
Evolus, a performance beauty company, announced participation in the H.C. Wainwright Global Investment Conference on May 24, 2022, from 9:00-9:30 am ET. The event aims to showcase Evolus's cutting-edge products, particularly Jeuveau®, a neurotoxin dedicated to aesthetics and FDA-approved in 2019. An audio webcast will be available on their website, with a replay for 90 days post-event. Evolus is committed to customer-centric innovation in the aesthetic market.
Evolus, Inc. (NASDAQ: EOLS) reported Q1 2022 net revenue of $33.9 million, a 177% increase from Q1 2021. The company now expects full-year revenue between $143 and $150 million, reflecting a nearly 50% year-over-year growth. Operating expenses rose to $49.4 million due to enhanced investments, while cash and equivalents stood at $106.7 million. Despite a $15.4 million operational loss, the company maintains a solid cash position to support its growth strategy and plans to launch Nuceiva® in Europe in Q3 2022.